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Efficacy of morning-only compared to split dose polyethylene glycol-electrolyte 
solution (PEG-ELS) for afternoon colonoscopy: A randomized controlled single-
blind study 
 
Rebecca Matro, M.D., Anastasia Shnitser, M.D., Maya Spodik, M.D., Constantine 
Daskalakis, Sc.D, Leo Katz, M.D., Alexandra Murtha, B.A., David Kastenberg, M.D. 
 
Abstract 
Objectives: Administering a purgative close to the time of colonoscopy is optimal for 
cleansing. The aim of this study was to compare the efficacy and tolerability of AM-only 
PEG-ELS to split dose (PM/AM) PEG-ELS for afternoon colonoscopy. 
 
Methods: Single center, prospective, randomized, investigator-blinded, non-inferiority 
study comparing AM-only to PM/AM PEG-ELS for afternoon outpatient colonoscopy. 
The primary endpoint was whole colon prep adequacy. Tolerance and polyp detection 
were secondary outcomes.  
 
Results: 125 patients were randomized and 9 withdrew without taking any prep. Of 116 
analyzed, 62 received AM-only prep and 54 received PM/AM prep. The whole colon 
prep was adequate in 92% in the AM-only group versus 94% in the PM/AM group (95% 
lower confidence limit, LCL, for the difference = -11.3%, non-inferiority p=0.013), while 
the right colon prep was adequate in 93% and 92%, respectively (95% LCL = -7.8%, 
non-inferiority p=0.003). Polyp detection was greater, and not inferior, in the AM-only 
group (mean = 1.57 versus 0.94 polyps/patient, non-inferiority p=0.007). The overall 
incidence of adverse events was not significantly different between the two groups 
(p=0.273), but the AM-only group had lower incidence of abdominal pain (p=0.024). The 
AM-only group also had better sleep quality (p=0.007) and less interference with the 
prior work day (p=0.019).   
 
Conclusion: AM-only and PM/AM PEG-ELS are clinically equivalent with respect to 
cleansing efficacy and polyp detection. AM-only prep was associated with a lower 
incidence of abdominal pain, superior sleep quality, and less interference with work day 
prior to colonoscopy. 
Introduction 
Recently supported in a position paper by the American College of 
Gastroenterology, superior colon cleansing is more likely if at least some of a purgative is 
ingested on the day of colonoscopy (1). Day-of-colon dosing can be achieved through 
two strategies – split (PM/AM) dosing where part of the purgative is administered the 
night prior to colonoscopy and the remainder within ~6 hours of the procedure, and 
morning-only (AM-only) dosing where the entire prep is taken on the day of colonoscopy 
(2-5). By linking the final dose of purgative to the timing of colonoscopy, a greater 
chance of adequate cleansing is assured regardless of the time of colonoscopy.  
There may be some distinct advantages to employing an AM-only dosing 
schedule in which colonoscopy, the prep and procedure, becomes a 1-day process. For 
one, it has the potential to minimize the prep’s interference on the patient’s ability to 
work and function the day prior.  Also, the impact on sleep may be diminished if no prep 
is consumed in the evening. Additionally, patients may perceive AM-only dosing as 
better tolerated since the predictable adverse events occur “once” on the day of procedure 
as compared to over two days.  Finally, this dosing regimen extends utilization of the 
endoscopy lab well into the afternoon (3). 
However, the potential disadvantages to AM-only dosing bear consideration. For 
some patients, such a regimen may not be practical for early morning procedures 
depending on the start time of the prep. Second, sodium phosphate cannot be utilized 
given the potential risk of administering a large dose over a short interval (6,7). Finally, 
though proven to be effective for AM-only dosing, 4L polyethylene glycol-electrolyte 
solution (PEG-ELS) administered all in the morning might be poorly tolerated (8).  
Utilizing a 2L PEG-ELS solution which does not require supplemental laxatives 
and is already FDA-approved for single (PM-only) and split dosing (PM/AM), we 
evaluated the efficacy, tolerance, and quality of life measures of AM-only dosing for 
afternoon colonoscopy. We hypothesized that AM-only 2L PEG-ELS is as effective as 
PM/AM dosing for achieving adequate cleansing and detecting polyps, and furthermore 
that this administration schedule improves quality of life by interfering less with the day 
prior to colonoscopy. 
 
Methods 
This was a prospective, randomized, investigator-blinded study, comparing AM-
only to PM/AM PEG-ELS dosing for patients undergoing afternoon colonoscopy. All 
patients provided written informed consent. The study was conducted at a single site in 
Philadelphia, PA, and was approved by the institution’s IRB. It was registered at 
ClinicalTrials.gov (http://www.clinicaltrials.gov), with identifier NCT00929916. 
Subjects 
Patients 18 years of age or older, scheduled to undergo elective outpatient 
afternoon (12 pm or later) colonoscopy at a university hospital were eligible to 
participate.  Exclusion criteria included pregnancy, breast feeding, known or suspected 
gastroparesis, chronic nausea or vomiting, bowel obstruction, hypomotility syndrome 
(pseudo-obstruction, megacolon, etc.), severe constipation (< 1 bowel movement a 
week), greater than 50% colon resection, known glucose-6-phospate dehydrogenase 
deficiency, PEG allergy, significant psychiatric illness, or inability to provide informed 
consent. 
Study design: Randomization and Protocol 
Using a randomization schedule generated by the website Randomization.com 
(http://www.randomization.com), eligible patients were assigned to AM-only or PM/AM 
PEG-ELS by an investigator not involved in the colonoscopy procedure. A commercially 
available 2L PEG-ELS containing sodium sulfate, sodium ascorbate, and ascorbic acid 
(MoviPrep®, Salix Pharmaceuticals, Morrisville, NC) was used. Subjects were provided 
with a standard PEG-ELS kit and given detailed instructions regarding preparation of the 
PEG-ELS, the administration of their assigned schedule, and routine preparation for 
colonoscopy including diet, hydration, and when to begin fasting. The patient’s 
endoscopist was not involved in the randomization process and remained blinded to the 
patient’s preparation schedule for the duration of the study. All study procedures were 
performed by an attending physician; fellows did not participate. 
Subjects assigned to AM-only administration took the first 1L dose seven hours 
before colonoscopy and the second 1L four hours before colonoscopy. Subjects 
randomized to PM/AM dose PEG-ELS were instructed to take the first liter (250 cc every 
15 minutes) plus 500 cc of clear liquids at 6 pm the night prior to colonoscopy, and the 
second liter four hours before colonoscopy.  
Diet instructions were identical for both study groups. On the day prior to 
colonoscopy, patients were permitted a low residue breakfast (before 10 am). Patients 
received instructions regarding a low residue diet, including a list of acceptable and 
unacceptable foods (Appendix A). After 10 am on the day prior to colonoscopy, patients 
were allowed clear liquids until 2.5 hours before colonoscopy at which point they took 
nothing further by mouth except for medications with sips of water. 
All subjects were called by an investigator who was not performing the 
colonoscopy within 1 week of their scheduled procedure and reminded about their 
colonoscopy appointment and specific preparation. On the day of their afternoon 
colonoscopy, patients arrived one hour prior to their scheduled procedure and met with an 
investigator who was not performing the colonoscopy. Patients completed several 
questionnaires evaluating compliance, tolerance, satisfaction, sleep, and work and 
productivity for the previous day. Tolerance was measured using a 10-point Likert scale, 
and patients rated side effects (nausea, vomiting, abdominal pain, lightheadedness, 
bloating) from 0 (none) to 10 (severe). Sleep quantity was measured by comparing the 
average number of hours the patient normally sleeps to the number of hours they slept the 
night prior to colonoscopy. Sleep quality was rated on a 5-point scale: very poor, poor, 
average, good, very good. Finally, work and productivity were measured using questions 
adapted from The Health and Labour Questionnaire (9). Patients rated how much their 
work, daily activities, and overall productivity were impaired by the preparation. Patients 
who went to work the day prior responded with strongly agree, agree, disagree, or 
strongly disagree to statements focused on whether they had trouble concentrating, had to 
work alone, could not do some work, or needed co-workers to do some work. Patients 
who did not have work the day before colonoscopy rated how much the preparation 
affected their household work, shopping and errands, child care, and other chores. A 
physician or registered nurse performed a safety assessment that included vital signs and 
physical exam. All patients got monitored anesthesia care (MAC) with propofol-based 
sedation administered by a certified registered nurse anesthetist.  
During the procedure, an investigator assisted the endoscopist in recording total 
procedure and withdrawal time (excluding interventions), cecal intubation, findings, and 
specific information regarding polyps, including the number, location, size, morphology, 
and method of excision. At the conclusion of the procedure, the endoscopist graded the 
quality of preparation for the whole colon and the right colon (excellent, good, fair, or 
poor) and estimated the amount of flushing required (none, <50 cc, 50-100 cc, or >100 
cc).  A descriptor of each preparation grade was available for the endoscopist to review at 
the time of assigning the grade (Appendix B). When final pathology reports became 
available for each patient, an investigator not involved in performing the colonoscopy 
recorded the following for each polyp: pathologic size, histology (hyperplastic, 
adenomatous, cancer, other), and additional histologic features for adenomas including 
grade of dysplasia (low grade, high grade) and the presence of a villous or serrated 
component. 
Masking 
To ensure blinding, patients were instructed by an investigator not to discuss their 
preparation assignment with the endoscopist. In addition, all preparation instructions 
were given in a closed exam room without the endoscopist present. At the time of 
colonoscopy, the endoscopists documented whether they had remained blind to the 
patients’ preparation through completion of the colonoscopy and grading of the prep.  
Outcome measures 
The primary trial endpoint was the dichotomous index of prep quality (adequate 
versus inadequate) for the whole colon. Adequate was defined as a good or excellent 
prep, and inadequate was defined as a fair or poor prep. The adequacy of cleansing for 
the right colon and the need for flush were secondary endpoints of prep quality. 
Additional secondary endpoints included prep completion, side effects (nausea, vomiting, 
abdominal pain, bloating, light-headedness), measures of quality of life (overall 
satisfaction, sleep quality, interference with work and overall productivity), and 
colonoscopy findings.  
Statistical analysis 
The analyses of the endpoints of prep quality and findings evaluated non-
inferiority of the AM-only prep compared to the PM/AM prep, with pre-specified 
margins. For prep quality, we expected about 90% of the cases in the PM/AM prep to be 
judged adequate, and the non-inferiority margin was set at -15% (i.e., the adequacy rate 
of the AM-only prep should not be lower than that of the PM/AM prep by more than 
15%). The study was designed to have 82% power to establish non-inferiority (using a 
one-sided test with alpha 0.05 and a target sample size of 110). The assumptions and pre-
specified non-inferiority margins for flush and the colonoscopy findings endpoints are 
summarized in Table 1. For each endpoint, we computed differences between the two 
groups, along with a one-sided 95% confidence interval and a one-sided p-value against 
the non-inferiority margin (with a significant p-value establishing non-inferiority). For 
the dichotomous endpoints, exact procedures were used. 
The analyses of the side effects and measures of quality of life tested superiority 
of the AM-only prep compared to the PM/AM prep. Fisher’s exact test was used for 
categorical variables, and t-test or the non-parametric Kruskall-Wallis test was used for 
continuous variables (all tests were two-sided, with alpha 0.05, with significant p-values 
establishing a difference between the two groups). All subjects were included in the 
group that they were assigned to, irrespective of whether (or when) they took their 
preparation doses. However, subjects who cancelled their colonoscopy after 
randomization did not provide any data and consequently were excluded from all 
analyses. The analyses were carried out in SAS 9.2 (SAS Institute Inc., Cary, NC) and 
StatXact 8 (Cytel Inc, Cambridge, MA). 
 
Results 
Participant flow and follow-up 
From October 2008 through April 2009, 125 patients referred for outpatient 
colonoscopy were initially randomized to AM-only or PM/AM prep (See Figure 1 Flow 
Diagram). However, 9 patients withdrew prior to taking any prep (5 patients cancelled 
their procedures and were unable to reschedule within the study time period, 1 patient 
required a morning procedure because of co-morbid conditions, 1 patient preferred a 
morning procedure, and 2 patients did not want to continue participating in the study), 
and therefore the analyses included 116 patients, of whom 62 received AM-only prep and 
54 received PM/AM prep. One patient in the AM-only group experienced 
nausea/vomiting and did not undergo colonoscopy but was included in the analyses of 
side effects and quality of life. The 115 procedures were performed by two endoscopists 
(with 110 of them performed by the study’s principal investigator, D.K.). Endoscopist 
masking was maintained for all but one case. Table 2 summarizes the characteristics of 
the study patients. Compared to PM/AM prep, the AM-only group had a somewhat 
greater number of women, and relatively fewer patients with a history of GERD and use 
of acid suppression medications, as well as cardiovascular disease (CVD).  
Prep Quality 
Prep quality was measured for the 115 patients who underwent colonoscopy and 
is summarized in Table 3. The colonoscopy was completed in all but one patient in the 
AM-only group whose procedure was aborted because of poor prep.  The whole colon 
prep was adequate for 56/61 (91.8%) patients in the AM-only group versus 51/54 
(94.4%) patients in the PM/AM group (95% lower confidence limit, LCL, for the 
difference = -11.3%, non-inferiority p = 0.013). The right colon prep was adequate for 
56/61 (93.3%) patients in the AM-only group versus 49/54 (92.5%) patients in the 
PM/AM group (95% LCL = -7.8%, non-inferiority p = 0.003). Withdrawal time, which 
consisted of the time spent inspecting the mucosa and excluded time for interventions, 
ranged from 3.8 to 24 minutes, with medians of 8.0 minutes in the AM-only group versus 
7.3 minutes in the PM/AM group (p = 0.637). Total procedure time, excluding time for 
interventions, ranged from 5.5 to 39 minutes, with medians of 12.8 versus 12.4 minutes, 
respectively (p = 0.147). The need for any flushing during the colonoscopy was similar 
between the study groups (26/61, 43%, in the AM-only group versus 28/54, 52%, in the 
PM/AM group, 95% upper confidence limit, UCL, for the difference = 6.4%, non-
inferiority p = 0.001, Table 3).  
Prep completion, side effects, and quality of life 
Table 4 summarizes prep completion, side effects, and measures of quality of life. 
Over 90% of both prep doses was taken by 84% (52/62) in the AM-only group versus 
72% (39/54) in the PM/AM group (95% confidence interval, CI, for the difference: -3.7% 
to 27.3%, p = 0.073). The overall incidence of side effects was not significantly different 
between the two groups, although abdominal pain (12/62, 19%, versus 21/54, 39%; 95% 
CI: -35.6% to -2.2%, p = 0.024) and light-headedness (18/62, 29%, versus 24/54, 46%, 
95% CI: -34.9% to 0.9%, p = 0.082) appeared less common in the AM-only group (Table 
4). After controlling for age, sex, history of cardiovascular disease, and use of acid 
suppression medications via logistic regression, the two groups remained different for the 
incidence of abdominal pain but not for light-headedness (adjusted p = 0.045 and 0.152, 
respectively). However, the severity of abdominal pain between the two groups was not 
significantly different (p = 0.144). One patient in the AM-only group who was severely 
obese (BMI = 40 kg/m2) aspirated during the procedure, was observed in the hospital for 
24 hours, and treated with one week of oral antibiotics.  
Duration of sleep the night prior to colonoscopy was not significantly different 
between the two groups (p = 0.675, Table 4), but the AM-only group had significantly 
better sleep quality (p = 0.007, Table 4). About a fifth of the patients in the AM-only 
group rated their sleep as “very good,” while this was the case for only a single patient in 
the PM/AM group. The proportion of patients that slept at least 80% of their typical hours 
was not significantly different between the groups (p = 0.675, Table 4).  
In the subset of patients who went to work the day prior to colonoscopy, the AM-
only group reported less interference with their ability to work (p = 0.019, Table 4). 
Overall satisfaction and the prep’s interference with overall productivity in everyday life 
were not significantly different between the two groups (p = 0.975 and 0.687, 
respectively, Table 4). The majority of patients favored repeating the same preparation in 
the future (51/62, 82%, in the AM-only group versus 43/54, 80%, in the PM/AM group, p 
= 0.814), and most maintained this preference even when the alternative prep schedule 
was explained and offered as an option (46/62, 74%, in the AM-only group versus 37/54, 
69%, in the PM/AM group, p = 0.541).   
Colonoscopy findings 
Table 5 summarizes polyp and adenoma/cancer detection. The average number of 
polyps per patient was 0.67 higher in the AM-only group (mean = 1.57 in AM-only 
versus 0.94 in PM/AM, 95% LCL for difference = 0.04, non-inferiority p = 0.007). 
Positive pathology findings included “low-risk” adenomas (low-grade dysplasia or 
serrated histology with size <1 cm), “high-risk” adenomas (high-grade dysplasia, villous 
histology, or size >1cm), or cancer. Compared to the PM/AM group, the AM-only group 
had an average of 0.24 more findings per patient (mean = 0.70 in AM-only versus 0.46 in 
PM/AM, 95% LCL for difference = -0.12, non-inferiority p = 0.047) and a greater 
detection rate for findings (22/60, 37%, versus 14/54, 26%, 95% LCL for difference = -
3.9, non-inferiority p = 0.038). The AM-only group also had a somewhat higher detection 
rate with respect to high-risk adenomas or cancer than the PM/AM group (8/60, 13%, 
versus 6/54, 11%), but the study precision was not sufficient to establish non-inferiority 
on such findings (95% LCL = -8.7, non-inferiority p = 0.282). 
 
Discussion 
An ideal colon purgative is safe, effective, and well tolerated. Despite more than 
14 million colonoscopies being performed each year, the historic rates for adequate 
cleansing are unacceptably low and range from 70-82% (10-13). Recent studies have 
shown that ingesting at least part of the purgative on the day of colonoscopy and 
coordinating the final dose of purgative with the start time of colonoscopy is more likely 
to result in adequate colon cleansing (2-5). Generally, this is accomplished by splitting 
the purgative between the evening prior and the morning of colonoscopy. This study 
expands the options for patients by demonstrating that ingestion of low volume PEG-ELS 
prep entirely on the day of colonoscopy is as good as a split dose schedule. 
Purgative ingestion entirely on the day of colonoscopy successfully met the pre-
defined quality endpoints, as compared to traditional split dosing. First and foremost, the 
rate of adequate cleansing for the whole colon was similarly high in the two groups (92% 
in the AM-only group and 94% in the PM/AM group). Adequate cleansing of the right 
colon, typically more difficult, was also similar and very high in both study arms (93% 
versus 92%, respectively). This rate of success, much higher than seen in retrospective 
studies often employing a long interval between prep and procedure, also affirms the 
importance of dosing the prep close to the time of colonoscopy (10-13). A non-inferiority 
design with respect to the primary endpoint of cleansing was utilized because split dosing 
typically produces a high level of adequate bowel preparation. Importantly, the trial 
results excluded big deficiencies in quality of the morning-only prep compared to the 
traditional split dosing. However, even though the study established non-inferiority using 
a margin of -15%, it is possible that the PM/AM prep may have somewhat better quality 
(although probably not by more than 10 percentage points or so). A further measure of 
colon cleanliness, the need for flushing, was also not inferior in the AM-only group (and 
in fact appeared somewhat better), compared to the PM/AM group. Finally, polyp 
detection and pathology findings (any adenoma or cancer) in the AM-only group were 
not less common than the PM/AM group (and the former even appeared more sensitive 
than the latter). The confidence intervals for these endpoints excluded any large 
differences in favor of the PM/AM prep. For the specific finding of high-risk adenomas 
or cancer, the AM-only group appeared slightly more sensitive than the PM/AM group, 
but the study failed to establish non-inferiority. This is probably due to a type II error as 
the study was underpowered to establish non-inferiority on an endpoint with such low 
event rate.   
Results on several adverse events and quality of life measures were mixed. 
Abdominal pain occurred significantly less often with AM-only dosing. The study failed 
to establish superiority of the AM-only dosing on other side effects, although some of 
those were somewhat less common in the AM-only group. The AM-only prep had better 
quality of sleep, but there was no difference between the two preps in duration of sleep. 
Perhaps apparent benefit on sleep quality was negated by the need to arise early in the 
AM-only group. For instance, a 12 pm (earliest start time) colonoscopy required the prep 
begin at 5 am for the AM-only group and 8 am for the PM/AM group. 
With respect to work, of patients who worked outside the home, only 56% in the 
PM/AM group and 64% in the AM-only group actually went to work the day before 
colonoscopy. Theoretically, PM/AM dosing should have little impact on the workday, 
and AM-only dosing none. All patients were permitted a low residue breakfast up to 10 
am, and then clear liquids up to 2.5 hours before the colonoscopy, but this restriction may 
have been enough to impact the work day. Among those who did go to work, patients in 
the AM-only group reported significantly less interference in the workday. The vast 
majority of patients in both groups found little to no impact of the preparation on overall 
productivity. Satisfaction was high for both groups and did not vary significantly between 
the two prep regimens. 
Several factors, in addition to dosing the purgative close to the time of 
colonoscopy, may have contributed to a high rate of adequacy for both groups. First, low 
volume PEG-ELS is better tolerated than four liter PEG purgatives, and likely leads to 
greater compliance (14,15). In addition, patients were carefully educated and supported 
throughout the pre-colonoscopy period. This has been shown to boost the success rate of 
colon preparation (16). The investigator consenting the patient provided detailed 
instructions on diet, purgative preparation and administration, and the possible side 
effects that might be experienced. With respect to diet, this was not highly restrictive as 
we chose a diet consisting of a low residue breakfast before 10 am on the day prior 
followed by clears up to 2.5 hours before colonoscopy. Though many physicians order a 
clear liquid diet for 24 hours, several studies support a less restrictive diet (4,17,18). 
A member of the research team uninvolved in grading the preparation called 
patients within one week of their scheduled procedure to remind them about their 
procedure, review their specific prep, and provide a contact number for patients to call for 
prep-related questions. Most patients undergoing routine colonoscopy do not have this 
degree of attention and support.  
Another consideration is that all but five colonoscopies were performed by one of 
the two endoscopists involved in this study. Though this should not have affected the 
non-inferiority results as the endoscopists were blinded to prep, if the predominant grader 
was “lenient” then colon grades could have all been inflated and resulted in overall high 
adequacy rates. Finally, these data likely only apply to patients undergoing afternoon 
colonoscopy.  
One patient in the AM-only group aspirated while under moderate sedation and 
developed aspiration pneumonia. Both groups of patients in the study presented herein 
were asked to complete the second dose of PEG-ELS 4 hours before their scheduled 
procedure time. Aspiration, though rare, is serious and has not been reported in several 
studies that have specifically evaluated PEG-ELS dosing on the day of colonoscopy (2-
5,8). Large published series of patients receiving propofol-based anesthesia for 
endoscopy have found aspiration to be a rare event. In one, of 2,000 healthy patients 
undergoing endoscopic procedures with nurse-administered propofol, there were five 
patients whose oxygen saturation fell to below 85% (19). Several conditions may be 
associated with increased incidence of pulmonary aspiration during general anesthesia, 
including extremes of age, male gender, pregnancy, difficult airway management, and 
factors that decrease gastric emptying, such as concurrent opioid administration, 
gastrointestinal obstruction or dysfunction, obesity, or depressed level of consciousness 
(20,21). Our patient who aspirated had no obvious risk factors for aspiration other than a 
BMI of 40 kg/m2, classifying her as morbidly obese. In patients who are high risk for 
aspiration, measures such as increasing the interval between the second purgative dose 
and the time of colonoscopy and/or reducing the prep volume consumed the day of 
colonoscopy may be prudent. 
In conclusion, our study showed that AM-only and PM/AM administration 
strategies for PEG-ELS are clinically equivalent with respect to cleansing efficacy, need 
for flushing, polyp detection, and adenoma or cancer detection. Furthermore, AM-only 
dosing was superior to PM/AM dosing with respect to some quality of life measures, as 
well as the incidence of prep-associated abdominal pain. These results support the notion 
that timing the last dose of purgative relative to the start time of colonoscopy results in a 
high rate of adequate colon cleansing, regardless of whether the prep is started the night 
prior or on the morning of colonoscopy. AM-only dosing is a viable option that moves 
the process of colonoscopy – prep and procedure – toward becoming a one-day 
procedure. While the paradigm has been for colonoscopy to be performed in the morning, 
linking the administration of the prep to the time of the procedure for both AM-only and 
PM/AM dosing may make late morning and afternoon colonoscopy equally or more 
attractive to patients in the future.   
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Figure 1. Patient assignment and disposition flow diagram 
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1. Table 1. Summary of assumptions and pre-specified non-inferiority margins for trial endpoints 
 
 Projected for 
PM/AM group 
Non-inferiority margin 
for AM-only group 
Prep quality adequate (% patients) 90% -15% 
Flush needed (% patients) 50% +25% 
Number of polyps per patient (mean) 1.0 -0.250 
Number of findings (adenomas or cancer) per 
patient (mean) 
0.5 -0.125 
Any adenoma or cancer found (% of patients) 20-25% -5% 
Any high-risk adenoma or cancer found  
(% patients) 10% -2.5% 
 
 
 
 
2. Table 2. Descriptive summary of characteristics of trial participants (N = 116) 
 
 PM/AM 
(N=54) 
AM-ONLY 
(N=62) 
Age, mean ± sd 51 ±  13 53 ±  11 
Sex, n (%)     
Female 
Male 
25 
29 
(46) 
(54) 
38 
24 
(61) 
(39) 
Indication, n (%)     
Screening 
Surveillance 
Symptoms 
28 
10 
16 
(52) 
(19) 
(30) 
31 
10 
21 
(50) 
(16) 
(34) 
First colonoscopy, n (%) 32 (59) 29 (47) 
Past medical history     
Diabetes, n (%) 
Thyroid disease, n (%) 
Hypertension, n (%) 
GERD, n (%) 
Inflammatory bowel disease, n (%) 
Pulmonary disease, n (%) 
Cardiovascular disease, n (%) 
Psychiatric disease, n (%) 
4 
2 
18 
8 
3 
2 
17 
6 
 (7) 
(4) 
(33) 
(15) 
(6) 
(4) 
(31) 
(11) 
5 
6 
17 
3 
2 
3 
11 
4 
 (8) 
(10) 
(27) 
(5) 
(3) 
(5) 
(18) 
(6) 
Prior surgery (any), n (%) 21 (39) 22 (35) 
Medications     
Antihypertensives, n (%) 
Cardiac medications, n (%) 
Acid suppression medications, n (%) 
Vitamins, herbs, and supplements, n (%) 
Other medications, n (%) 
18 
16 
9 
5 
19 
(33) 
(30) 
(17) 
(9) 
(35) 
22 
15 
4 
9 
17 
(35) 
(24) 
(6) 
(15) 
(27) 
 
 
 
 
3. Table 3. Measures of prep quality (N = 115) 
 
 PM/AM 
(N=54) 
AM-ONLY 
(N=61*) 
p (non-inferiority) 
Prep quality: whole colon, n (%)     0.013 
Adequate (excellent/good) 
Inadequate (fair/poor) 
51 
3 
(94) 
(6) 
56 
5 
(92) 
(8) 
 
Prep quality: whole colon, n (%)      
Excellent 
Good 
Fair 
Poor 
23 
28 
3 
0 
(43) 
(52) 
(6) 
 
25 
31 
1 
4 
(41) 
(51) 
(2) 
(7) 
 
Prep quality: right colon,** n (%)     0.003 
Adequate (excellent/good) 
Inadequate (fair/poor) 
49 
4 
(92) 
(8) 
56 
4 
(93) 
(7) 
 
Prep quality: right colon,* n (%)      
Excellent 
Good 
Fair 
Poor 
17 
32 
3 
1 
(32) 
(60) 
(6) 
(2) 
29 
27 
3 
1 
(48) 
(45) 
(5) 
(2) 
 
Flush needed, n (%)     0.001 
None 
Any 
26 
28 
(48) 
(52) 
35 
26 
(57) 
(43) 
 
Flush needed, n (%)      
None 
<50 ml 
50-100 ml 
>100 ml 
26 
14 
4 
10 
(48) 
(26) 
(7) 
(19) 
35 
13 
8 
5 
(57) 
(21) 
(13) 
(8) 
 
 
(*) Prep quality not assessed for a single patient who did not undergo colonoscopy 
(**) Data not available for two patients (one in each group) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4. Table 4. Prep completion, side effects, and quality of life (N = 116) 
 
 PM/AM 
(N=54) 
AM-ONLY 
(N=62) 
p (difference) 
Completion of >90% of both doses, n (%) 39 (72) 52 (84) 0.175 
Any side effect, n (%) 45 (82) 44 (72) 0.273 
Nausea, n (%) 
Vomiting, n (%) 
Abdominal pain, n (%) 
Bloating, n (%) 
Light-headedness, n (%) 
Other side effect, n (%) 
23 
3 
21 
35 
25 
12 
(43) 
(6) 
(39) 
(65) 
(46) 
(22) 
24 
6 
12 
31 
18 
7 
(39) 
(10) 
(19) 
(50) 
(29) 
(11) 
0.708 
0.500 
0.024 
0.134 
0.082 
0.136 
Overall satisfaction* (0-10 scale), median [IQR] 2 [0, 5] 4 [1, 4] 0.975 
Slept for >80% of usual hours, n (%) 41 (76) 44 (71) 0.675 
Sleep quality, n (%)     0.007 
Very good 
Good 
Average 
Poor 
Very poor 
1 
23 
21 
8 
1 
(2) 
(43) 
(39) 
(15) 
(2) 
12 
13 
24 
11 
2 
(19) 
(21) 
(39) 
(18) 
(3) 
 
Went to work,** n (%) 22 (56) 27 (64) 0.503 
Interference with work,*** n (%)     0.019 
None 
1-25% 
26-50% 
51-75% 
>75% 
12 
6 
3 
0 
1 
(55) 
(27) 
(14) 
 
(5) 
23 
3 
0 
1 
0 
(85) 
(11) 
 
(4) 
 
Interference with overall productivity, n (%)     0.687 
None 
1-25% 
26-50% 
51-75% 
>75% 
25 
18 
3 
5 
3 
(46) 
(33) 
(6) 
(9) 
(6) 
34 
21 
2 
4 
1 
(55) 
(34) 
(3) 
(6) 
(2) 
 
 
(*) Likert scale 0 = highly satisfied, 10 = highly dissatisfied 
(**) Only among patients who routinely work outside the home (39 in PM/AM group and 42 in AM-only 
group) 
(***) Only among patients who went to work (22 in PM/AM group and 27 in AM-only group) 
 
 
 
 
 
 
 
 
 
 
 
 
 
5. Table 5. Colonoscopy findings (N = 114) 
 
 PM/AM 
(N=54) 
AM-ONLY 
(N=60*) 
p (non-inferiority) 
Number of polyps**, mean (sd) 0.94 (1.6) 1.57 (2.1) 0.007 
Number of polyps**, n (%)      
0 
1 
2 
3 
4 
5+ 
33 
9 
3 
4 
3 
2 
(61) 
(17) 
(6) 
(7) 
(6) 
(4) 
27 
10 
9 
4 
3 
7 
(45) 
(17) 
(15) 
(7) 
(5) 
(12) 
 
Any polyps detected, n (%) 21 (39) 33 (55)  
Number of findings*** per patient, mean (sd) 0.46 (1.0) 0.70 (1.3) 0.047 
Number of findings per patient, n (%)      
0 
1 
2 
3+ 
40 
7 
5 
2 
(74) 
(13) 
(9) 
(4) 
38 
14 
2 
6 
(63) 
(23) 
(3) 
(10) 
 
Pathology finding, n (%)      
No polyps, hyperplasia, or benign 
Low-risk adenoma+ 
High-risk adenoma∝ 
Cancer 
40 
8 
5 
1 
(74) 
(15) 
(9) 
(2) 
38 
14 
7 
1 
(63) 
(23) 
(12) 
(2) 
 
Any finding***, n (%) 14 (26) 22 (37) 0.038 
High-risk adenoma or cancer, n (%) 6 (11) 8 (13) 0.282 
 
(*) Findings not available for two patients, one who did not undergo colonoscopy and another whose 
colonoscopy was aborted due to very poor prep 
(**) Number of polyps refers to all polyps 
(***) Finding includes adenoma or cancer 
(+) Low-risk includes low-grade dysplasia or serrated adenomas that are <1 cm 
(∝) High-risk includes any of the following: villous, high-grade dysplasia, or size ≥1 cm 
 
 
 
Study Highlights 
 
What is current knowledge 
• Optimal colon cleansing requires purgative administration close to the time of 
colonoscopy. Traditionally, split dosing has been used. 
• Alternatively, the prep can be taken entirely in the morning 
What is new here 
• AM-only prep is as effective as PM/AM prep for achieving adequate colon 
cleansing for afternoon colonoscopy. 
• Patients taking AM-only prep had significantly less abdominal pain, better sleep 
quality, and less interference with the work day prior. 
 
 References 
 
1. Rex DK, Johnson DA, Anderson JC et al. American College of Gastroenterology 
Guidelines for Colorectal Cancer Screening 2009. Am J Gastroenterol 2009;104:739-
750. 
2. Parra-Blanco A, Nicolas-Perez D, Gimeno-Garcia A et al. The timing of bowel 
preparation before colonoscopy determines the quality of cleansing, and is a 
significant factor contributing to the detection of flat lesions: A randomized study. 
World J Gastroenterol 2006;12:161-6. 
3. Chiu H-M, Lin J-T, Wang H-P et al. The impact of colon preparation timing on 
colonoscopic detection of colorectal neoplasms—A prospective endoscopist-blinded 
randomized trial. Am J Gastroenterol 2006;101:2719-25. 
4. Aoun E, Abdul-Baki H, Azar C et al. A randomized single-blind trial of split-dose 
PEG-electrolyte solution without dietary restriction compared with whole dose PEG-
electrolyte solution with dietary restriction for colonoscopy preparation. Gastrintest 
Endosc 2005;62:213-8. 
5. El Sayed AM, Kanafani ZA, Mourad FH et al. A randomized single-blind trial of 
whole versus split-dose polyethylene glycol-electrolyte solution for colonoscopy 
preparation. Gastrointest Endosc 2003;58:36-40. 
6. Caswell M, Thompson WO, Kanapka JA et al. The time course and effect on serum 
electrolytes of oral sodium phosphates solution in healthy male and female 
volunteers. Can J Clin Pharmacol 2007;14:e260-74. 
7. Rex DK. Dosing considerations in the use of sodium phosphate bowel preparations 
for colonoscopy. Ann Pharmacother 2007;41:1466-75. 
8. Church, JM. Effectiveness of polyethylene glycol antegrade gut lavage bowel 
preparation for colonoscopy—timing is the key! Dis Colon Rectum 1998;41:1223-5. 
9. Hakkaart-van Roijen L, Essink-Bot ML. The Health and Labour Questionnaire. 
Institute for Medical Technology Assessment 2000. 
10. Harewood GC, Sharma VK, de Garmo P. Impact of colonoscopy preparation quality 
on detection of suspected colonic neoplasia. Gastrointest Endosc 2003;58:76-9. 
11. Ness RM, Manam R, Hoen H et al. Predictors of inadequate bowel preparation for 
colonoscopy. Am J Gastroenterol 2001;96:1797-1802. 
12. Hsu C-W, Imperiale TF. Meta-analysis and cost comparison of polyethylene glycol 
lavage versus sodium phosphate for colonoscopy preparation. Gastrointest Endosc 
1998;48:276-82. 
13. Tan JJ, Tjandra JJ. Which is the optimal bowel preparation for colonoscopy – a meta-
analysis. Colorectal Dis 2006;8:247-58. 
14. DiPalma JA, Wolff BG, Meagher A et al. Comparison of reduced volume versus four 
liters sulfate-free electrolyte lavage solutions for colonoscopy colon cleansing. Am J 
Gastroenterol 2003;98:2187-91. 
15. Ell C, Fischbach W, Bronisch H-J et al. Randomized trial of low-volume PEG 
solution versus standard PEG + electrolytes for bowel cleansing before colonoscopy. 
Am J Gastroenterol 2007;102:1-11. 
16. Abuksis G, Mor M, Segal N et al. A patient education program is cost-effective for 
preventing failure of endoscopic procedures in a gastroenterology department. Am J 
Gastroenterol. 2001;96:1786-1790. 
17. Reilly T, Walker G. Reasons for poor colonic preparation for inpatients. 
Gastroenterol Nurs 2004;27:115-7. 
18. Adams WJ, Meagher AP, Lubowski DZ et al. Bisacodyl reduces the volume of 
polyethylene glycol solution required for bowel preparation. Dis Colon Rectum 
1994;37:229-34. 
19. Rex DK, Overley C, Kinser K et al. Safety of propofol administered by registered 
nurses with gastroenterologist supervision in 2000 endoscopic cases. Am J 
Gastroenterol 2002;97:1159-63. 
20. Olsson GL, Hallen B, Hambraeus-Jonzon K. Aspiration during anaesthesia: A 
computer-aided study of 185,358 anaesthetics. Acta Anaesthesiol Scand 1986;30:84-
92. 
21. Warner M, Warner M, Weber J. Clinical significance of pulmonary aspiration during 
the perioperative period. Anesthesiology 1993;78:56-62. 
 
Conflict of Interest/Study Support 
 
Guarantor of the article: David Kastenberg, M.D. 
 
Specific author contributions: The authors’ responsibilities were as follows: D.K. had 
full access to all the data in the study and takes responsibility for the integrity of the data 
and the accuracy of the data analyses. D.K., C.D.: study concept and design; D.K., L.K: 
contributed patients to the study and performed the study colonoscopies; R.M., A.S., 
M.S., A.M.: randomization assignment, patient consent and instructions, distribution of 
MoviPrep®, data collection; C.D.: data analyses and interpretation; R.M., D.K., C.D.: 
drafting and revision of manuscript. All authors approved the final draft for submission. 
 Financial support: Salix Pharmaceuticals, Inc. funded this study and provided 
MoviPrep® for all patients. The sponsor of this study had no role in study design, data 
collection, data analysis, data interpretation, or writing of the report. 
 
Potential competing interests: D.K is a speaker and consultant for and receives research 
support from Salix Pharmaceuticals, Inc. 
